Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on May 17, 2013, involving a connected person of Director Sir Andrew Witty:
- Transfer of 219 Ordinary Shares from a bare trust.
- Repurchase of 215 Ordinary Shares into an Individual Savings Account (ISA).
- Transaction prices were 1703.3483p and 1703.865p per share, respectively.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the total shareholding of Sir Andrew Witty's connected person following the May 17, 2013 transactions.
- Confirm the pricing of the shares against the market price on the transaction date.
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this notification.